Master in Sustainable

Drug Discovery

Master in short

2 years

The S-DISCO programme is a 2-year full-time Master programme.

4 universities

The programme is organized by 4 European universities, i.e. Ghent University, Medical University of Gdańsk, University of Lille and the University of Groningen.

Master thesis

Students will perform a master thesis in one of the partner institutions or with one of the numerous associated partners (incl. industry, competent authorities and research institutions).

Master degree

Successful students will obtain a common master of science degree of the partner universities.

Target students

Candidates must hold a higher education diploma (180 ECTS or higher) in Chemical, Biological, (Bio-)Engineering, Pharmaceutical or Medical sciences.

Get involved

S-DISCO Programme

Learn about the S-DISCO programme and how to apply.

Our partners

The S-DISCO master degree has been built through close collaboration between the consortium and industrial players in the field in order to train high-level graduates with inter-and trans-disciplinary skills in the different fields of drug discovery, with a focus on sustainability. The partners will actively participate in the S-DISCO programme by i.a. teaching, holding seminars and providing internships to master thesis students. Discover our partners

What to expect?

Find out what students can expect when they are selected for the S-DISCO programme.


Last month, our students organized the first Sustainable Drug Discovery (S-DISCO) Days in Gdańsk, Poland. This yearly international scientific conference aims to raise awareness and expand the knowledge on sustainability in drug discovery for students, scientists and experts from various institutions and industries. We would like to thank the students for the perfect organization, the […]
Today is Europe Day! On 9 May every year we celebrate peace and unity in Europe. How will you celebrate the occasion?
End of April, the European Commission has released its proposal for major change in the human pharmaceutical legislation, undoubtedly making the system more sustainable. One of the key changes is the importance of the environmental risk assessment (ERA), in line with the European Green Deal. The ERA rightfully now becomes a possible reason for not […]

“Finding adequate treatments for unmet disease conditions, for everyone, everywhere, at a fair price, while respecting the environment and ecosystems is an enormous challenge, and one that we must be better prepared for.”

Bart De Spiegeleer, Ghent University

Scroll to Top